Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Hepatobiliary disposition of atovaquone: A case of mechanistically unusual biliary clearance.

Patel M, Johnson M, Sychterz CJ, Lewis GJ, Watson C, Ellens H, Polli JW, Zamek-Gliszczynski MJ.

J Pharmacol Exp Ther. 2018 Apr 13. pii: jpet.117.247254. doi: 10.1124/jpet.117.247254. [Epub ahead of print]

2.

Derivation of a System-Independent Ki for P-glycoprotein Mediated Digoxin Transport from System-Dependent IC50 Data.

Chaudhry A, Chung G, Lynn A, Yalvigi A, Brown C, Ellens H, O'Connor M, Lee C, Bentz J.

Drug Metab Dispos. 2018 Mar;46(3):279-290. doi: 10.1124/dmd.117.075606. Epub 2018 Jan 9.

PMID:
29317410
3.

Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites.

Ellens H, Johnson M, Lawrence SK, Watson C, Chen L, Richards-Peterson LE.

Drug Metab Dispos. 2017 Jun;45(6):646-656. doi: 10.1124/dmd.116.073932. Epub 2017 Mar 20.

PMID:
28320730
4.

Extrapolation of Elementary Rate Constants of P-glycoprotein-Mediated Transport from MDCKII-hMDR1-NKI to Caco-2 Cells.

Meng Z, Ellens H, Bentz J.

Drug Metab Dispos. 2017 Feb;45(2):190-197. doi: 10.1124/dmd.116.072140. Epub 2016 Nov 16.

5.

Microvilli Morphology Can Affect Efflux Active P-Glycoprotein in Confluent MDCKII -hMDR1-NKI and Caco-2 Cell Monolayers.

Meng Z, Le Marchand S, Agnani D, Szapacs M, Ellens H, Bentz J.

Drug Metab Dispos. 2017 Feb;45(2):145-151. doi: 10.1124/dmd.116.072157. Epub 2016 Nov 16.

6.
7.

A novel application of t-statistics to objectively assess the quality of IC50 fits for P-glycoprotein and other transporters.

O'Connor M, Lee C, Ellens H, Bentz J.

Pharmacol Res Perspect. 2015 Feb;3(1):e00078. doi: 10.1002/prp2.78. Epub 2014 Dec 2.

8.

Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.

Lee CA, O'Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-Gliszczynski MJ.

Drug Metab Dispos. 2015 Apr;43(4):490-509. doi: 10.1124/dmd.114.062174. Epub 2015 Jan 13. Review.

9.

A structural model for the mass action kinetic analysis of P-gp mediated transport through confluent cell monolayers.

Bentz J, Ellens H.

Methods Mol Biol. 2014;1113:289-316. doi: 10.1007/978-1-62703-758-7_14.

PMID:
24523118
10.

Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humans.

Dave M, Nash M, Young GC, Ellens H, Magee MH, Roberts AD, Taylor MA, Greenhill RW, Boyle GW.

Drug Metab Dispos. 2014 Mar;42(3):415-30. doi: 10.1124/dmd.113.054486. Epub 2013 Dec 30.

11.

The importance of villous physiology and morphology in mechanistic physiologically-based pharmacokinetic models.

Chen EP, Tai G, Ellens H.

Pharm Res. 2014 Feb;31(2):305-21. doi: 10.1007/s11095-013-1161-x. Epub 2013 Aug 30.

PMID:
23990312
12.

Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.

Lumen AA, Li L, Li J, Ahmed Z, Meng Z, Owen A, Ellens H, Hidalgo IJ, Bentz J.

PLoS One. 2013 Aug 16;8(8):e69394. doi: 10.1371/journal.pone.0069394. eCollection 2013.

13.

Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.

Ellens H, Deng S, Coleman J, Bentz J, Taub ME, Ragueneau-Majlessi I, Chung SP, Herédi-Szabó K, Neuhoff S, Palm J, Balimane P, Zhang L, Jamei M, Hanna I, O'Connor M, Bednarczyk D, Forsgard M, Chu X, Funk C, Guo A, Hillgren KM, Li L, Pak AY, Perloff ES, Rajaraman G, Salphati L, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yamagata T, Lee CA.

Drug Metab Dispos. 2013 Jul;41(7):1367-74. doi: 10.1124/dmd.112.050542. Epub 2013 Apr 25.

14.

Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.

Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, Pak YA, Perloff ES, Reyner E, Balimane P, Brännström M, Chu X, Funk C, Guo A, Hanna I, Herédi-Szabó K, Hillgren K, Li L, Hollnack-Pusch E, Jamei M, Lin X, Mason AK, Neuhoff S, Patel A, Podila L, Plise E, Rajaraman G, Salphati L, Sands E, Taub ME, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yabut J, Yamagata T, Zhang L, Ellens H.

Drug Metab Dispos. 2013 Jul;41(7):1347-66. doi: 10.1124/dmd.112.050500. Epub 2013 Apr 25.

15.

ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, Nagar S, Pang KS, Korzekwa K, Swaan PW, Taub ME, Zhao P, Galetin A; International Transporter Consortium.

Clin Pharmacol Ther. 2013 Jul;94(1):64-79. doi: 10.1038/clpt.2013.45. Epub 2013 Feb 25. Review.

16.

Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations.

Bloomer J, Derimanov G, Dumont E, Ellens H, Matheny C.

Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):737-51. doi: 10.1517/17425255.2013.781582. Epub 2013 Apr 16. Review.

PMID:
23586918
17.

Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.

Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE.

Chem Res Toxicol. 2012 Oct 15;25(10):2067-82. doi: 10.1021/tx300075j. Epub 2012 Sep 19.

PMID:
22931300
18.

Fitting the elementary rate constants of the P-gp transporter network in the hMDR1-MDCK confluent cell monolayer using a particle swarm algorithm.

Agnani D, Acharya P, Martinez E, Tran TT, Abraham F, Tobin F, Ellens H, Bentz J.

PLoS One. 2011;6(10):e25086. doi: 10.1371/journal.pone.0025086. Epub 2011 Oct 18.

19.

Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodium-dependent transporter expressed in HEK293 cells.

Taub ME, Mease K, Sane RS, Watson CA, Chen L, Ellens H, Hirakawa B, Reyner EL, Jani M, Lee CA.

Drug Metab Dispos. 2011 Nov;39(11):2093-102. doi: 10.1124/dmd.111.040816. Epub 2011 Aug 17.

20.

A mechanism-based mathematical model of aryl hydrocarbon receptor-mediated CYP1A induction in rats using beta-naphthoflavone as a tool compound.

Chen EP, Chen L, Ji Y, Tai G, Wen YH, Ellens H.

Drug Metab Dispos. 2010 Dec;38(12):2278-85. doi: 10.1124/dmd.110.034421. Epub 2010 Sep 15.

21.

Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.

Xu CF, Reck BH, Xue Z, Huang L, Baker KL, Chen M, Chen EP, Ellens HE, Mooser VE, Cardon LR, Spraggs CF, Pandite L.

Br J Cancer. 2010 Apr 27;102(9):1371-7. doi: 10.1038/sj.bjc.6605653. Epub 2010 Apr 13.

22.
23.

Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay.

Thiel-Demby VE, Humphreys JE, St John Williams LA, Ellens HM, Shah N, Ayrton AD, Polli JW.

Mol Pharm. 2009 Jan-Feb;6(1):11-8. doi: 10.1021/mp800122b.

PMID:
19248229
24.

Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.

Acharya P, O'Connor MP, Polli JW, Ayrton A, Ellens H, Bentz J.

Drug Metab Dispos. 2008 Feb;36(2):452-60. Epub 2007 Oct 29.

25.

P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites.

Acharya P, Tran TT, Polli JW, Ayrton A, Ellens H, Bentz J.

Biochemistry. 2006 Dec 26;45(51):15505-19. Epub 2006 Nov 30.

PMID:
17176072
26.
27.

The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.

Tran TT, Mittal A, Aldinger T, Polli JW, Ayrton A, Ellens H, Bentz J.

Biophys J. 2005 Jan;88(1):715-38. Epub 2004 Oct 22.

28.

Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier.

Tran TT, Mittal A, Gales T, Maleeff B, Aldinger T, Polli JW, Ayrton A, Ellens H, Bentz J.

J Pharm Sci. 2004 Aug;93(8):2108-23.

PMID:
15236458
29.

Physiological considerations in the design of particulate dosage forms for oral vaccine delivery.

Yeh P, Ellens H, Smith PL.

Adv Drug Deliv Rev. 1998 Dec 1;34(2-3):123-133.

PMID:
10837674
30.

Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity.

Stenberg P, Luthman K, Ellens H, Lee CP, Smith PL, Lago A, Elliott JD, Artursson P.

Pharm Res. 1999 Oct;16(10):1520-6.

PMID:
10554092
31.

Endothelin receptor antagonists.

Elliott JD, Ohlstein EH, Peishoff CE, Ellens HM, Lago MA.

Pharm Biotechnol. 1998;11:113-29. Review. No abstract available.

PMID:
9760678
32.

Size-dependent permeability of hydrophilic probes across rabbit colonic epithelium.

Ghandehari H, Smith PL, Ellens H, Yeh PY, Kopecek J.

J Pharmacol Exp Ther. 1997 Feb;280(2):747-53.

33.

Water-in-oil microemulsions containing medium-chain fatty acids/salts: formulation and intestinal absorption enhancement evaluation.

Constantinides PP, Welzel G, Ellens H, Smith PL, Sturgis S, Yiv SH, Owen AB.

Pharm Res. 1996 Feb;13(2):210-5.

PMID:
8932438
34.

Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.

Ohlstein EH, Nambi P, Lago A, Hay DW, Beck G, Fong KL, Eddy EP, Smith P, Ellens H, Elliott JD.

J Pharmacol Exp Ther. 1996 Feb;276(2):609-15.

PMID:
8632328
35.

Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides.

Constantinides PP, Scalart JP, Lancaster C, Marcello J, Marks G, Ellens H, Smith PL.

Pharm Res. 1994 Oct;11(10):1385-90.

PMID:
7855039
36.
37.

Fusion of influenza virus with sialic acid-bearing target membranes.

Alford D, Ellens H, Bentz J.

Biochemistry. 1994 Mar 1;33(8):1977-87.

PMID:
8117654
38.

Delivery of liposome-encapsulated RNA to cells expressing influenza virus hemagglutinin.

Glenn JS, Ellens H, White JM.

Methods Enzymol. 1993;221:327-39. No abstract available.

PMID:
7689688
39.

Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.

Hart TK, Kirsh R, Ellens H, Sweet RW, Lambert DM, Petteway SR Jr, Leary J, Bugelski PJ.

Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2189-93.

40.

Soluble CD4 and dextran sulfate mediate release of gp120 from HIV-1: implications for clinical trials.

Bugelski PJ, Ellens H, Hart TK, Kirsh RL.

J Acquir Immune Defic Syndr. 1991;4(9):923-4. No abstract available.

PMID:
1895215
41.

An architecture for the fusion site of influenza hemagglutinin.

Bentz J, Ellens H, Alford D.

FEBS Lett. 1990 Dec 10;276(1-2):1-5.

42.

Fusion of influenza hemagglutinin-expressing fibroblasts with glycophorin-bearing liposomes: role of hemagglutinin surface density.

Ellens H, Bentz J, Mason D, Zhang F, White JM.

Biochemistry. 1990 Oct 16;29(41):9697-707.

PMID:
2271610
43.

Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1.

Kirsh R, Hart TK, Ellens H, Miller J, Petteway SA Jr, Lambert DM, Leary J, Bugelski PJ.

AIDS Res Hum Retroviruses. 1990 Oct;6(10):1209-12. No abstract available.

PMID:
2252640
44.

Physiological levels of diacylglycerols in phospholipid membranes induce membrane fusion and stabilize inverted phases.

Siegel DP, Banschbach J, Alford D, Ellens H, Lis LJ, Quinn PJ, Yeagle PL, Bentz J.

Biochemistry. 1989 May 2;28(9):3703-9.

PMID:
2751991
45.

Membrane fusion and inverted phases.

Ellens H, Siegel DP, Alford D, Yeagle PL, Boni L, Lis LJ, Quinn PJ, Bentz J.

Biochemistry. 1989 May 2;28(9):3692-703.

PMID:
2751990
46.

Delivery of macromolecules into cells expressing a viral membrane fusion protein.

Ellens H, Doxsey S, Glenn JS, White JM.

Methods Cell Biol. 1989;31:155-78. No abstract available.

PMID:
2779447
47.

Destabilization of phosphatidylethanolamine-containing liposomes: hexagonal phase and asymmetric membranes.

Bentz J, Ellens H, Szoka FC.

Biochemistry. 1987 Apr 21;26(8):2105-16.

PMID:
3620441
48.

Fusion of phosphatidylethanolamine-containing liposomes and mechanism of the L alpha-HII phase transition.

Ellens H, Bentz J, Szoka FC.

Biochemistry. 1986 Jul 15;25(14):4141-7.

PMID:
3741846
49.

Destabilization of phosphatidylethanolamine liposomes at the hexagonal phase transition temperature.

Ellens H, Bentz J, Szoka FC.

Biochemistry. 1986 Jan 28;25(2):285-94.

PMID:
3954998
50.

Supplemental Content

Loading ...
Support Center